PHESGO® is a subcutaneous combination of pertuzumab and trastuzumab for HER2-positive breast cancer, designed to reduce treatment time.
Related products
Ozempic 0.25mg Injection (UK)
Semaglutide
Wegovy 1.7mg/0.7ml Inj. x 1Pen
Semaglutide Injection
Zoladex 10.8mg Inj. x 1 (NAFDAC)
Wegovy 2.4mg/0.7ml Inj. x 1Pen
Semaglutide Injection















